Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.58 |
| ▸ | GLS | O94925 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 3/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435795 | 1.00 | MTNR1A (0.58) | MTNR1AMTNR1BGLSCYP2C19SMN1; SMN2 | |
| SCHEMBL4333359 | 0.85 | CYP2C19 (0.52) | CYP2C19SMN1; SMN2APAF1POLBPTGFR | |
| SCHEMBL28290228 | 0.85 | CYP2C19 (0.52) | CYP2C19SMN1; SMN2APAF1POLBPTGFR | |
| SCHEMBL8089702 | 0.84 | MTNR1A (0.43) | MTNR1AMTNR1BGLSSMN1; SMN2POLB | |
| SCHEMBL5370889 | 0.84 | MTNR1A (0.54) | MTNR1AMTNR1BGLSCYP2C19 | |
| SCHEMBL2091812 | 0.82 | MTNR1A (0.67) | MTNR1AMTNR1BAPAF1BCAT2NPC1 | |
| SCHEMBL6655475 | 0.82 | MTNR1A (0.51) | MTNR1AMTNR1BGLSSMN1; SMN2 | |
| SCHEMBL6209721 | 0.81 | BCAT2 (0.66) | CYP2C19SMN1; SMN2APAF1POLBPTGFR | |
| SCHEMBL11480585 | 0.81 | TAAR1 (0.52) | CYP2C19SMN1; SMN2APAF1POLB | |
| SCHEMBL11436581 | 0.81 | MTNR1A (0.62) | MTNR1AMTNR1BSMN1; SMN2APAF1BCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | MTNR1A 178/4885MTNR1B 285/4885GLS 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.